Location History:
- Princeton, NJ (US) (2010)
- Pasadena, CA (US) (2007 - 2011)
Company Filing History:
2 out of 4,770 
1 out of 2,405 
1 out of 4,548 
Years Active: 2007-2011
Title: Teresa Beeson: Innovator in Diabetes Therapeutics
Introduction
Teresa Beeson is a prominent inventor based in Pasadena, California, known for her significant contributions to the field of pharmacology, particularly regarding diabetes treatment. With a total of four patents to her name, she has made substantial advancements in therapeutic compounds aimed at managing type 2 diabetes.
Latest Patents
Among her latest inventions are two noteworthy patents. The first, titled "Substituted Pyrazoles, Compositions Containing Such Compounds and Methods of Use," details compounds that function as glucagon receptor antagonists. These compounds are pivotal for treating, preventing, or delaying the onset of type 2 diabetes mellitus. The second patent, "Pyrazole Amide Derivatives, Compositions Containing Such Compounds and Methods of Use," focuses on pyrazole amides, which are similarly useful for treating type 2 diabetes and its related conditions. This patent also encompasses various pharmaceutical compositions and methods of treatment.
Career Highlights
Teresa’s career has been marked by her roles in leading pharmaceutical companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. Her work in these firms has allowed her to refine her expertise and focus on innovations that directly impact health outcomes for individuals managing diabetes.
Collaborations
Throughout her career, Teresa has collaborated with esteemed colleagues, including Emma R. Parmee and Subharekha Raghavan. These partnerships have contributed to her success and the development of groundbreaking treatments.
Conclusion
Teresa Beeson's innovative work in the field of diabetes therapeutics is characterized by her dedication and collaboration with other experts. Her patents not only highlight her ingenuity but also offer promising solutions for the management of type 2 diabetes, reflecting her significant role in advancing pharmaceutical research and innovation.